Quantcast

Latest National Institute for Health and Clinical Excellence Stories

2011-08-26 07:00:00

NICE guidance for laparoscopic cryotherapy of renal cancer outlines an improved patient pathway for those seeking renal cryotherapy as a first line treatment. Galil Medical provided NICE with broad clinical evidence supporting the safety and efficacy of renal cryotherapy procedures. Arden HIlls, MN (PRWEB) August 26, 2011 Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, announced today that NICE (National Institute for Health and Clinical Excellence)...

health-082411-001
2011-08-24 14:20:15

  Diagnoses and treatment of blood pressure is on the verge of being revolutionized following new guidelines for the medical profession by the National Institute for Health and Clinical Excellence (NICE) and British Hypertension Society (BHS). The new guidelines mark the first time in more than a century that the way blood pressure is monitored by health professionals has been changed. More than 25 percent of patients may have been misdiagnosed for high blood pressure. Taking...

2011-01-18 14:30:12

A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced today (18th January 2011). A previous appraisal by NICE of these drugs in 2004 approved the use of donepezil,...

2010-07-08 18:00:00

HIGH WYCOMBE, England, July 9, 2010 /PRNewswire/ -- - In a draft appraisal the National Institute for Health and Clinical Excellence (NICE) has refused to recommend the first treatment shown to improve survival in childhood bone cancer (osteosarcoma) in more than 20 years(1,2) - Data shows Mepact(R) (mifamurtide) reduces the risk of death by almost one third when added to standard chemotherapy treatment, compared with chemotherapy alone(3) -...

2010-06-28 07:00:00

SUNNYVALE, Calif., June 28 /PRNewswire/ -- BARRX Medical Inc., a world leader in products to treat pre-cancerous tissue in the esophagus, reported today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has published new guidelines approving the use of radiofrequency ablation for the eradication of dysplastic Barrett's esophagus. Barrett's esophagus is a precancerous condition that affects over 6.6 million people around the world and is caused by...

2010-06-04 13:43:41

Analysis: Multiple sclerosis risk sharing scheme: A costly failure The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around £50m per year since it was set up in 2002. They also point out that, if an assessment had been completed after the first two years,...

2010-05-17 05:59:00

RA'ANANA, Israel, May 17, 2010 /PRNewswire-FirstCall/ -- NICE Systems Ltd. (NASDAQ: NICE), a leading global provider of advanced solutions that enable enterprises and security organizations to extract Insight from Interactions, transactions and surveillance to drive business performance, reduce risk and ensure safety, today announced that the Port or Los Angeles has begun implementation of NICE Situator, an open platform situation management solution. The NICE solution will provide an...

2010-04-01 08:35:00

INDIANAPOLIS, April 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE). Specifically, NICE's Final Appraisal Determination recommends ALIMTA as an option for the maintenance treatment of people with locally advanced or metastatic non-small cell lung...

2010-03-29 18:01:00

PARIS, March 30, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD)[1] for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation (AF). The NICE appraisal committee's preliminary recommendation is to endorse...

2010-02-26 09:20:50

Analysis: New drugs for old: disinvestment and NICE Decisions about which drugs to abandon to fund new treatments recommended by the National Institute for Health and Clinical Excellence (NICE) are inconsistent and may be contributing to the postcode lottery "“ one of the key issues that NICE was set up to tackle, warn experts on bmj.com Feb. 25. Dyfrig Hughes and Robin Ferner argue that the methods for identifying drugs that can be discontinued need to be as rigorous as those for...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related